News
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study...
Sermonix to Present Poster on Oncologists’ Perception of Sexual Intimacy Issues in Treatment of Metastatic Breast Cancer at 2019 North American Menopause Society Annual Meeting
Sept. 26 presentation in Chicago demonstrates the need for improvement in practitioners’...
Sermonix Poster Presentation at 2019 ASCO Annual Meeting Demonstrates Promise for Lasofoxifene in Treating ER+ Metastatic Breast Cancer Patients With ESR1 Mutations
Sermonix-sponsored University of Chicago preclinical investigation demonstrated: Lasofoxifene...
Lasofoxifene Shows Promise as Treatment for ER-Positive Metastatic Breast Cancer
CHICAGO—Findings suggest that lasofoxifene, in combination with CDK4/6 inhibitors like...
Sermonix Receives FDA Fast Track Designation for Investigational Drug Lasofoxifene
Designation allows for expedited development and review of lasofoxifene as a potential precision...
Sermonix to Present Poster on ‘Lasofoxifene as a Potential Treatment for ER+ Metastatic Breast Cancer’ at 2019 ASCO Annual Meeting
Biopharmaceutical company studied combination of lasofoxifene and CDK4/6 inhibitor palbociclib...
Sermonix Pharmaceuticals Adds Three New Members to Its Board of Directors
Richard U. DeSchutter, Michael A. Friedman and Stephen Rubino bring decades of diverse C-level...
Sermonix to Present at Boston Oncology Investor Conference on Potential for Lasofoxifene in Metastatic Breast Cancer Treatment
COLUMBUS, Ohio, March 11, 2019 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals LLC, a privately held...
Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer
Biopharmaceutical company collaborated with Ben May Department for Cancer Research at University...
To sign up for future Sermonix press releases, please enter your information below.